The Pharmacy and Poisons Board has approved the use of a prescription drug for the treatment of prostate cancer.
The drug, ZYTIGA (abiraterone acetate), is manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson.
The local pharmacy regulator has approved the use of the once-daily medication for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.
“The drug is only licensed for the treatment of advanced prostate cancer cases post-chemotherapy,” Janssen Kenya Country Manager Marseille Onyango said.
Nationwide protests, held in all 16 regional capitals, had been staged by the NDC on Tuesday, demanding an independent audit…
Consequently, the UAE announced a set of new humanitarian projects in Chad and pledged $10.25 million to the United Nations…
Loveness Bhitoni has been picking baobab fruit from the gigantic trees surrounding his farm in Zimbabwe since childhood, to vary…
A terrorist attack by the Al-Qaeda affiliate group Jama'a Nusrat ul-Islam wa al-Muslimin-or JNIM-occurred in Bamako, Mali, early Tuesday, September…
The Afrika Tikkun youth development agency has teamed up with Microsoft South Africa to launch the ICT Academy - Going…
Over a year after the fighting in Sudan between the Sudanese army and RSF paramilitaries, civilians are caught in a…
This website uses cookies.